Group 1 - The company, Sanofi Pharmaceutical-B (02257), announced the completion of the issuance of 1,003,700 new shares based on a subscription agreement dated September 7, 2025 [1]

智通财经APP讯，圣诺医药-B(02257)发布公告，于2025年12月8日，该公司根据2025年9月7日的认购协 议，完成根据一般授权认购新股份后发行的100.37万股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 聖諾醫藥 (*僅供識別) 呈交日期： 2025年12月8日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02257 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | | 每股發行/出售價 (註4) | | 已發行股份總數 | | | | 已 ...

Core Viewpoint - The company has partially completed the subscription agreement B on December 7, 2025, issuing 1.0037 million new shares at HKD 12.00 per share, while agreeing to terminate the remaining subscription of 2.1513 million shares without any claims between the parties involved [1] Group 1 - The company and subscriber B mutually agreed to terminate the remaining subscription of 2.1513 million shares, rendering all rights and obligations void, with no claims allowed between the parties [1] - The board believes that the termination of the remaining shares will not have any significant adverse impact on the company's existing business, operations, or financial condition [1] Group 2 - Subscriber C failed to fulfill its obligations under subscription agreement C by December 7, 2025, leading the company to terminate this agreement as well [1] - Similar to agreement B, the termination of agreement C also results in all rights and obligations being void, with no claims permitted between the parties [1] - The board asserts that the termination of subscription agreement C will not significantly affect the company's current business, operations, or financial status [1]

经友好诚信协商后，公司与认购人B一致同意于2025年12月7日终止认购余下2,151,286股股份("余下股 份")。于该终止后，订约方全部权利及义务即告失效，任何一方均不得就认购协议B向另一方提出任何 索偿。董事会认为，终止认购余下股份不会对公司现有业务、营运或财务状况产生任何重大不利影响。 格隆汇12月7日丨圣诺医药-B(02257.HK)公告，认购协议B于2025年12月7日部分完成，并以每股认购股 份12.00港元向认购人B发行1,003,700股新股份。 ...

Core Viewpoint - The company has partially completed the subscription agreement B on December 7, 2025, issuing 1.0037 million new shares at HKD 12.00 per share to subscriber B, while agreeing to terminate the remaining subscription of 2.1513 million shares without any significant adverse impact on its business, operations, or financial condition [1] Group 1 - The company and subscriber B mutually agreed to terminate the remaining subscription of 2.1513 million shares on December 7, 2025, resulting in the expiration of all rights and obligations under subscription agreement B [1] - The board believes that the termination of the remaining shares will not have any significant adverse impact on the company's existing business, operations, or financial condition [1] Group 2 - Subscriber C failed to fulfill its obligations under subscription agreement C by December 7, 2025, leading the company to terminate this agreement as well [1] - Similar to agreement B, the termination of agreement C will not have any significant adverse impact on the company's existing business, operations, or financial condition [1]

香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 之 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 概 不 對 因本 公 告 全部 或 任 何 部 分內 容 而 產 生或 因 倚 賴 該 等內 容 而 引 致 之任 何 損 失 承擔 任何責任。 Sirnaomics Ltd. 聖 諾 醫 藥 * 下表載列(i)緊接部分完成前；及(ii)緊隨部分完成後的股權架構： （ 於開曼群島註冊成立之有限公司） （股份代號：2257） 部分完成根據一般授權認購新股份及 終止認購協議 茲提述Sirnaomics Ltd.（「本公司」）日期為2025年9月7日及2025年9月17日有 關 認 購 事 項 之 公 告（「該 等 公 告」）。 除 文 義 另 有 所 指 外 ， 本 公 告 所 用 詞 彙 與 該等公告所界定者具有相同涵義。 部分完成認購協議B 認購協議B於2025年12月7日部分完成，並以每股認購股份12.00港元向認購 人B發行1,003,700股新股份（「部分完成」）。 經友好誠信協商後，本公司與 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 聖諾醫藥 (*僅供識別) 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02257 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 230,000,000 | USD | | 0.001 | USD | | 230,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 230,000,000 | USD | | 0.001 | USD | | 230,000 | 本月底法定/註冊股本 ...

Group 1 - The Hong Kong biotechnology sector experienced a widespread decline, with notable drops in several companies' stock prices [1] - Specifically, Gilead Sciences-B fell over 13%, while Sanofi-B dropped more than 10% [1] - Other companies such as Crystal Technology Holdings and Hualing Pharmaceutical-B also saw declines exceeding 6% [1] Group 2 - Gilead Sciences-B's latest price is 11.750, with a market capitalization of 116.56 billion and a year-to-date increase of 290.37% [2] - Sanofi-B's latest price is 7.000, with a market capitalization of 7.44 billion and a year-to-date increase of 102.31% [2] - Crystal Technology Holdings has a latest price of 9.330, a market capitalization of 401.48 billion, and a year-to-date increase of 56.02% [2] - Hualing Pharmaceutical-B's latest price is 3.230, with a market capitalization of 34.13 billion and a year-to-date increase of 121.23% [2] - Other companies like Wangshan Wangshui-B and Sanleaf Biotech-B also reported significant declines, with year-to-date increases of 123.25% and 920.75% respectively [2]

Core Viewpoint - The Hong Kong pharmaceutical stocks experienced a significant downturn, with notable declines in several companies' stock prices [1] Group 1: Company Performance - Gilead Sciences (歌礼制药-B) saw a drop of over 8% in its stock price [1] - Sanofi (圣诺医药-B) experienced a decline of more than 6% [1] - Deciphera Pharmaceuticals (德琪医药-B) fell by over 4% [1] - Other companies such as Innovent Biologics (复宏汉霖) and Antengene Corporation (药捷安康-B) also followed the downward trend [1]